User Review
( votes)
As 2021 is drawing to a close, it’s turning out to be the biggest year ever in biopharma venture capital, both in terms of total funding and the size of rounds. Biotech companies have raised over $32 billion in IPOs in 2021, with special-purpose acquisition companies accounting for one-third of IPOs while outperforming conventional IPOs by 2x in terms of capital raised.
